1. Proteomic characterization of plasma-derived clotting factor VIIIâvon Willebrand factor concentrates
- Author
-
Feilei Huang, James Clifton, Spomenka Kovač, Xinli Yang, Djuro Josic, and Douglas C. Hixson
- Subjects
Proteomics ,congenital, hereditary, and neonatal diseases and abnormalities ,clotting factor VIII ,proteomic analysis ,prothrombin ,von Willebrand factor ,Clinical Biochemistry ,Tandem mass spectrometry ,Fibrinogen ,Biochemistry ,Article ,Analytical Chemistry ,Von Willebrand factor ,Tandem Mass Spectrometry ,hemic and lymphatic diseases ,von Willebrand Factor ,medicine ,Humans ,Blood Coagulation ,Clotting factor ,Chromatography ,Factor VIII ,biology ,Chemistry ,Fibronectins ,Blood proteins ,Fibronectin ,biology.protein ,circulatory and respiratory physiology ,medicine.drug - Abstract
Proteomic methods were used to identify the levels of impurities in three commercial plasma-derived clotting factor VIII-von Willebrand factor (FVIII/VWF) concentrates. In all three concentrates, significant amounts of other plasma proteins were found. In Octanate and Haemoctin, two concentrates developed in the 1990s, the major impurities identified were inter-alpha inhibitor proteins, fibrinogen and fibronectin. These two concentrates were also found to contain additional components such as clotting factor II (prothrombin) that are known activators of FVIII. In Wilate, a recently developed FVIII/VWF concentrate, the amount of these impurities was significantly reduced. Batch-to-batch variations and differences between three investigated products were detected using iTRAQ, an isotope labeling technique for comparative mass spectrometry, demonstrating the potential value of this technique for quality control analysis. The importance of thorough proteomic investigations of therapeutic F VIII/VWF preparations from human plasma is also discussed.
- Published
- 2009
- Full Text
- View/download PDF